Skip to main content

Table 4 Characteristics of the 33 selected randomised controlled trials and the patients studied in them

From: A meta-analysis of the efficacy of fibromyalgia treatment according to level of care

N Randomized controlled trial Year Country Treatment Level of care % of women Mean age Length of treatment (years) Simple size Oxford scoring (quality) Duration of disease at baseline (years) Instruments used (outcome assessed)
1 Carette 94 Canada Amitryptiline Cyclobenzaprine Primary care 93.8 44.4 24 208 3 7.7 Mc Gill-BPI (p) SIP (gf)
2 Russell 94 USA Malic acid Specialised care 90 49.5 8 24 3   VAS (p) TPI (tp)
3 Wolfe 94 USA Fluoxetine Primary care 100 50.4 3 42 5 13 TPI (tp) BDI (ad)
4 Carette 95 Canada Amitryptiline Primary care 95.5 43.8 8 22 2 6.9 VAS (p) VAS (i) VAS (gf)
5 Chesky 95 USA Music vibration Specialised care 92.6 48.8 30 minutes 26 3 11 VAS (p) TPI (tp)
6 Goldenberg 96 USA Fluoxetine Amitryptiline Primary care 90.3 43 6 31 5 5.7 VAS (p) FIQ (GF) BDI (ad) VAS (i) VAS (gf) VAS (f) TPI (tp)
7 Ginsberg 96 Belgium Amitryptiline Primary care 82.5 46 8 46 2 32 VAS (p) VAS (i) TPI (tp) VAS (f) VAS (gf) NTP (tp)
8 Moldofsky 96 Canada Zolpidem Primary care 95 42 2.5 19 4   NTP (tp) PGI (i)
9 Vlayen 96 Holland Cognitive behavioural therapy Education training Specialised care 87 44 6 131 5 10 BDI (ad)
10 Wigers 96 Norway Aerobic exercise Stress-reduction treatment Specialised care 92 44 14 48 3 10 VAS (p) VAS (i) VAS (f)
11 Pearl 96 Canada Bright light treatment Specialised care 100 38 10 14 2 5 VAS (p) VAS (f) VAS (i)
12 Kelli 97 Canada Chiropractic treatment Specialised care - 49 4 19 4 8 VAS (p) NTP (tp)
13 Hannonen 98 Finland Moclobemide Amitryptiline Primary care 100 49 12 130 5 11.2 NTP (tp) VAS (p) VAS (f) VAS (i)
14 Yavuzer 98 Turkey Moclobemide Primary care 58 33 6 60 1   TPI (tp)
15 Ginsberg 98 Belgium Pirlindole Specialised care 85 40 4 61 4 2.9 VAS (p) TPI (tp) VAS (gf)
16 Russell 00 USA Tramadol Primary care 94 49 6 69 4 4.7 VAS (p) FIQ (gf) NTP (tp)
17 Heymann 01 Brazil Amitryptiline Nortryptiline Primary care 100 50 8 118 4   FIQ (gf) NTP (tp)
18 Färber 01 Germany Tropisetron Specialised care 92 48 1.5 403 3 11 Vas (p) NTP (tp)
19 Gowans 01 Canada Exercise Specialised care 88 47 23 50 3 9 FIQ (gf) BDI (ad) STAI (ad) NTP (tp)
20 Mannerkorpi 01 Sweden Education training Specialised care 100 46 24 58 4 8.7 FIQ (gf) QOLS (ql)
21 Gür 02 Turkey Laser Amitryptiline Primary care (Amytriptiline) – Specialised care (laser) 80 30 8 75 3 4.6 HADS (ad) FIQ (gf)
22 Joaquim 02 Sweden Education training Behavioural therapy Specialised care 100 45 12 53 6 3.6 pain FIQ (gf) Mc Gill (p)
23 King 02 Canada Exercise Education training Specialised care 100 46 12 152 4   FIQ (gf) NTP (tp)
24 Lemstra 05 Canada Rehabilitation Specialised care 84.5 49.5 6 79 3 10 VAS (p) BDI (ad)
25 Schachter 03 Canada Aerobic exercise (long-term and short-term) Specialised care 100 42 16 143 4 3.5 VAS (p) FIQ (gf)
26 Arnold 04 USA Duloxetine Primary care 88 49 12 207 6 8.9 BDI (ad) BPI (ad) NTP (tp) CGI (gf) FIQ (gf)
27 Yildiz 04 Turkey Hyperbaric oxigen therapy Specialised care 70 40 2.5 50 2 4.5 VAS (p) NTP (tp)
28 Crofford 05 USA Pregabaline Primary care 92 48.5 8 529 5 9 VAS (p) MAF (f)
29 Arnold 05 USA Duloxetine Primary care 100 50 12 354 5   BPI (ad)
30 Gendreau 05 USA Milnacipran Primary care 98 47 12 125 6 4.1 FIQ (gf)
31 Finckh 05 Switzerland Dehydroepiandrosterone (DHA) Specialised care 100 59 12 52 6 13 HADS (ad) VAS (f)
32 Holman 05 USA Pramipexole Specialised care 94.4 48.5 14 60 6 8.4 BDI (ad) HAMD (ad) TPI (tp) FIQ (gf)
33 Edinger 05 USA Cognitive behavioural therapy Sleep hygiene Specialised care 100 49 6 47 3   Mc Gill (p) BPI (ad) SF-36 (ql)
  1. Outcome types: P, Pain; QL, Quality of life; AD, Anxiety-depression; I, Insomnia; TP, Tender points; F, Fatigue; GF, Global Function.
  2. Questionnaires: Mc Gill PQ, Mc Gill Pain Questionnaire; BPI, Brief Pain Inventory; VAS, Visual Analogue Scale; QOLS, Quality of Life Scale; BDI, Beck Depression Inventory; HADS, Hospital Anxiety and Depression Scale; HDS, Hamilton Depression Scale; STAI, State-trait Anxiety Inventory; PGI, Patient Global Impression; TPI, Tender Points Index; MAF, Multi-dimensional Assessment of Fatigue; FIQ, Fibromyalgia Impact Questionnaire; CGIS, Clinical Global Impression of Severity; SIP, Sickness Impact Profile.